AstraZeneca-Bristol Myers Talks Spark Share Moves, Analyst Skepticism

Pharmaceutical investors faced sudden volatility Monday after reports emerged of merger discussions between AstraZeneca and Bristol Myers Squibb that could create a roughly $400 billion combined entity. AstraZeneca shares fell as much as 7 percent in London trading before closing down 4.7 percent, while Bristol Myers shares rose 6 to 8 percent in U.S. premarket activity, according to market data cited by multiple outlets.

The talks, first reported by the Financial Times, remain unconfirmed. AstraZeneca declined to comment. Bristol Myers did not respond outside regular U.S. business hours. Sources cited by the Financial Times indicated a deal is not certain to proceed. AstraZeneca entered the day with a market capitalization of $264 billion; Bristol Myers stood near $133 billion.

The central tension lies in strategic fit. AstraZeneca has posted steady gains under chief executive Pascal Soriot since 2012, lifting its market value more than fourfold and setting a target of $80 billion in annual sales by 2030, up from $58.7 billion last year. Bristol Myers faces patent expirations on major products including Eliquis and Opdivo beginning next year. Analysts at Jefferies described themselves as perplexed, noting AstraZeneca does not require financial engineering. RBC Capital Markets highlighted upcoming trial readouts for Bristol Myers’ milvexian and Cobenfy that complicate immediate pipeline synergies.

Overlaps exist in oncology, cardiovascular disease and immunology. AstraZeneca holds stronger positions in solid tumors; Bristol Myers emphasizes blood cancers and cell therapies. Jefferies analysts warned that a combined oncology portfolio would rank among the industry’s broadest and would likely draw antitrust review. Citi analysts called any such transaction a surprise given AstraZeneca’s pipeline strength.

AstraZeneca completed a direct listing on the New York Stock Exchange earlier this year. U.S. sales accounted for 42 percent of its first-half 2026 revenue. Bristol Myers derived 69 percent of recent quarterly revenue from the United States. The British company has committed $50 billion to U.S. research and manufacturing by 2030.

A week before the reports, AstraZeneca disclosed that a late-stage trial of its heart-disease candidate Wainua missed its primary endpoint. Bristol Myers separately beat second-quarter expectations and raised its 2026 outlook, reporting $12.97 billion in revenue. John Murphy of Bloomberg Intelligence stated that the companies’ differing growth trajectories—double-digit gains projected for AstraZeneca through 2030 versus expected declines at Bristol Myers—make a merger of limited strategic sense. History shows mega-mergers can slow pipeline progress, he added.

AstraZeneca was formed in 1999 from the merger of Astra AB and Zeneca Group. It rejected a 2014 takeover approach from Pfizer valued at nearly £70 billion. Bristol Myers employs about 800 people in the United Kingdom, including 250 in research at Moreton on the Wirral.